Senti Biosciences (Nasdaq: SNTI) is a clinical-stage biotechnology firm based in South San Francisco. It focuses on cell and gene therapies built around its Gene Circuit platform, which aims to equip therapeutic cells with better environmental sensing and response capabilities.
The lead candidate, SENTI-202, represents a potentially first-in-class Logic Gated, off-the-shelf CAR-NK cell therapy. It is advancing through an open-label, multi-center Phase 1 trial targeting relapsed or refractory blood cancers such as acute myeloid leukemia. While pipeline updates draw attention, the company generates little revenue and posts consistent losses, leaving it reliant on outside capital and exposed to market volatility.
Over the past 30 days, SNTI declined about 71.8% on a split-adjusted basis, moving from a closing level near $6.29 down to $1.77. That drop combined ongoing selling pressure with a significant structural adjustment.
The three-month picture shows an even sharper fall, with shares sliding from roughly $12.82 to $1.77, or about 86%. Prices had touched near $15 in mid-August before a steady descent that picked up speed amid compliance worries and financing questions. The reverse split lifted the quote temporarily, yet the stock resumed its downward path right after the adjustment took effect.
The standout event was the 1-for-33 reverse stock split. Management announced it on November 17, 2026, completed the filing the next day, and began split-adjusted trading on November 19. The action sought to push the price back above Nasdaq’s $1.00 minimum bid level after prolonged trading below that threshold.
While the split itself leaves the economic value of holdings unchanged, it highlighted underlying business pressures. On August 27, 2026, Nasdaq had flagged that shares had closed below $1.00 for 30 straight sessions and that stockholders’ equity no longer met exchange standards. Restoring compliance became a top priority. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Further context came from a November 9, 2026, $4.55 million equity commitment with a Celadon Partners affiliate, with shares to be issued at the minimum price in quarterly settlements through late 2027. That raised dilution concerns. Third-quarter results showed a narrowed net loss of $11.59 million versus $18.13 million a year earlier, yet cash consumption stayed in focus.
The broader quarterly decline stems from a larger restructuring effort. In July 2026 the company signed a merger agreement with ST NewCo Limited and related parties; shareholders approved it at the reconvened annual meeting in mid-October. The structure includes contingent value rights linked to future milestones, introducing uncertainty around near-term value.
Financing steps, including senior secured convertible notes and the equity commitment noted earlier, were pursued to support operations amid a strained balance sheet. Negative equity, ongoing losses, and the need to meet Nasdaq rules created steady downward pressure throughout the period.
Several items will likely influence the path ahead. Maintaining the Nasdaq listing and making progress on both bid-price and equity-compliance requirements remain essential. Updates on the ST NewCo merger, including any contingent value rights, will also draw attention. Clinical advancement of SENTI-202 and the ability to raise capital without heavy dilution are equally important, as are cash-burn trends and any regulatory or partnership news. These points are for informational purposes only.
In my own research process, I frequently reference Tickeron’s Trending AI Robots to review data-driven strategies that complement fundamental analysis. The platform highlights top-performing bots across different timeframes and approaches, offering a practical way to cross-check market signals without replacing individual judgment.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where SNTI declined for three days, in 274 of 311 cases, the price declined further within the following month. The odds of a continued downward trend are 88%.
The Moving Average Convergence Divergence Histogram (MACD) for SNTI turned negative on November 17, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 39 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 80%.
The Aroon Indicator for SNTI entered a downward trend on November 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 11 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +16.23% 3-day Advance, the price is estimated to grow further. Considering data from situations where SNTI advanced for three days, in 194 of 237 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
SNTI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 33 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-1.465) is normal, around the industry mean (3.596). P/E Ratio (-0.095) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (166.667) is also within normal values, averaging (443.347).
The Tickeron Price Growth Rating for this company is 97 (best 1 - 100 worst), indicating slightly worse than average price growth. SNTI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SNTI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry Biotechnology